Danielle Antalffy
Stock Analyst at UBS
(3.25)
# 1,043
Out of 4,711 analysts
172
Total ratings
44.55%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Initiates: Buy | $52 | $33.66 | +54.49% | 2 | Dec 6, 2024 | |
| GKOS Glaukos | Initiates: Buy | $182 | $150.88 | +20.63% | 1 | Dec 6, 2024 | |
| SGHT Sight Sciences | Initiates: Buy | $5.5 | $3.57 | +54.06% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $364.60 | +1.48% | 6 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Buy | $35 → $40 | $30.72 | +30.21% | 12 | Oct 30, 2024 | |
| ABT Abbott Laboratories | Maintains: Buy | $143 → $146 | $114.23 | +27.81% | 11 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $74.81 | +0.25% | 12 | Sep 10, 2024 | |
| MDT Medtronic | Upgrades: Neutral | $76 → $90 | $81.03 | +11.07% | 7 | Aug 15, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $107.12 | -0.11% | 4 | Aug 8, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Neutral | $6.5 → $7 | $6.96 | +0.57% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $80.04 | +18.69% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $90 | $88.95 | +1.18% | 11 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $26 | $17.08 | +52.22% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $43.12 | +73.93% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $144.47 | +24.59% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $187.77 | +71.49% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $3.09 | -27.18% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $29.50 | +45.76% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $524.43 | -46.99% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $35.91 | +25.31% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $266.57 | +5.04% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $55 | $1.21 | +4,445.45% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $15.64 | -10.49% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $89.29 | +12.00% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $11.53 | +4.08% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $81.17 | -63.04% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $56.50 | -20.35% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $85 | $3.79 | +2,142.74% | 10 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $55.45 | +71.33% | 6 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $227.68 | +20.78% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.05 | +555.74% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $8.48 | +395.28% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.46 | +552.46% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.92 | +1,539.34% | 1 | Sep 1, 2020 |
RxSight
Dec 6, 2024
Initiates: Buy
Price Target: $52
Current: $33.66
Upside: +54.49%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $150.88
Upside: +20.63%
Sight Sciences
Dec 6, 2024
Initiates: Buy
Price Target: $5.5
Current: $3.57
Upside: +54.06%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $364.60
Upside: +1.48%
AtriCure
Oct 30, 2024
Maintains: Buy
Price Target: $35 → $40
Current: $30.72
Upside: +30.21%
Abbott Laboratories
Oct 17, 2024
Maintains: Buy
Price Target: $143 → $146
Current: $114.23
Upside: +27.81%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $74.81
Upside: +0.25%
Medtronic
Aug 15, 2024
Upgrades: Neutral
Price Target: $76 → $90
Current: $81.03
Upside: +11.07%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $107.12
Upside: -0.11%
Treace Medical Concepts
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $6.96
Upside: +0.57%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $80.04
Upside: +18.69%
Apr 25, 2024
Maintains: Buy
Price Target: $74 → $90
Current: $88.95
Upside: +1.18%
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $17.08
Upside: +52.22%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $43.12
Upside: +73.93%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $144.47
Upside: +24.59%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $187.77
Upside: +71.49%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $3.09
Upside: -27.18%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $29.50
Upside: +45.76%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $524.43
Upside: -46.99%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $35.91
Upside: +25.31%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $266.57
Upside: +5.04%
May 5, 2022
Maintains: Outperform
Price Target: $65 → $55
Current: $1.21
Upside: +4,445.45%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $15.64
Upside: -10.49%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $89.29
Upside: +12.00%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $11.53
Upside: +4.08%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $81.17
Upside: -63.04%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $56.50
Upside: -20.35%
Feb 24, 2022
Maintains: Outperform
Price Target: $105 → $85
Current: $3.79
Upside: +2,142.74%
Feb 24, 2022
Maintains: Outperform
Price Target: $85 → $95
Current: $55.45
Upside: +71.33%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $227.68
Upside: +20.78%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.05
Upside: +555.74%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $8.48
Upside: +395.28%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.46
Upside: +552.46%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.92
Upside: +1,539.34%